Vyvanse® (lisdexamfetamine) is a stimulant medication used for the treatment of attention deficit hyperactivity disorder (ADHD), approved for use in patients 6 years of age and older. On August 28, the generic lisdexamfetamine was approved, and pharmacies are beginning to receive this product. For Ohio Medicaid patients, brand name Vyvanse® is the preferred option as of September 2023. Generic lisdexamfetamine will not be covered without a prior authorization. When issuing a prescription for Vyvanse® for Ohio Medicaid patients, prescribers can mark the prescription with Dispense As Written 9 (DAW 9). A DAW 9 code instructs the pharmacy that the patient’s insurance requests the brand name product over a generic. Using this code should prevent a pharmacy from automatically filling a generic product. For more information on the approval, see the FDA below.